CJC-1295 No DAC 5 mg

Peptide Hubs CJC-1295 No DAC

CJC-1295 No DAC, also known as Modified GRF (1-29), is a precision-engineered 5 mg lyophilized powder representing the gold standard in growth hormone-releasing hormone (GHRH) research peptides. This truncated, modified analog contains the first 29 amino acids of GHRH with key substitutions (including the addition of Norleucine) that dramatically increase its stability and potency while eliminating the Drug Affinity Complex (DAC) that causes continuous release. With a third-party lab test confirming a purity of 4.78 mg per vial, researchers receive an accurately dosed compound. For bodybuilders and athletes engaged in performance research, CJC-1295 No DAC offers a powerful tool for investigating the stimulation of natural, pulsatile growth hormone secretion—mimicking the body's own physiological patterns to support fat loss, muscle growth, and recovery.

CJC-1295 No DAC Composition

Each sterile 2 mL vial contains 5 mg of the synthetic peptide CJC-1295 No DAC, with the sequence: H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2. The modifications include the replacement of the first amino acid (Alanine) with D-Alanine and the addition of Norleucine at position 27, which protect it from enzymatic degradation (DPP-IV cleavage). The product is supplied as a pure, white lyophilized powder without fillers, requiring reconstitution with bacteriostatic water before use in research protocols.

Bodybuilding and Athletic Research Benefits

In research models, CJC-1295 No DAC is studied for its potent ability to stimulate the natural pulsatile release of growth hormone (GH) and subsequently Insulin-like Growth Factor 1 (IGF-1). This leads to several investigational benefits for body composition and performance: enhanced lipolysis (fat burning) and reduced adipose tissue, improved nitrogen retention and protein synthesis for muscle growth support, accelerated recovery from intense training through increased collagen synthesis and cell regeneration, and potential improvements in sleep quality and connective tissue strength. Unlike exogenous GH, it promotes the body's own endogenous, pulsatile GH secretion, which may offer a more natural anabolic and metabolic research profile.

Therapeutic and Research Indication

While a research chemical, CJC-1295 (in various forms) has been clinically studied for growth hormone deficiency. As a GHRH analog, it binds to the GHRH receptor on pituitary somatotroph cells, stimulating the synthesis and pulsatile release of endogenous GH. The "No DAC" version is particularly interesting because it avoids the continuous, non-physiological GH release associated with the DAC version. The science behind GHRH analogs is well-established, with resources like the National Institutes of Health (NIH) publishing on the physiology of the GH/IGF-1 axis.

Mechanism of Action: Pulsatile GH Release

CJC-1295 No DAC works by mimicking the action of endogenous Growth Hormone-Releasing Hormone (GHRH). It binds with high affinity to the GHRH receptors on the anterior pituitary gland. This binding activates intracellular signaling pathways (primarily via cAMP) that stimulate the synthesis and secretion of stored growth hormone in a sharp, pulsatile manner—similar to the body's natural nocturnal and post-exercise GH pulses. The "No DAC" designation means it lacks the Drug Affinity Complex that binds to albumin, resulting in a short half-life (approximately 30 minutes) and preventing constant, baseline GH elevation, which is crucial for maintaining natural feedback loops.

Dosage for Research (Men)

Research protocols for CJC-1295 No DAC capitalize on its short half-life and pulsatile nature. Common investigative doses range from 100 mcg to 300 mcg per administration. It is typically administered via subcutaneous injection 2-3 times daily to mimic natural GH pulses, with key doses taken before bedtime (to amplify nocturnal pulses) and post-workout. Many research designs pair it with a GHRP (like Ipamorelin or GHRP-2) for synergistic effects. Cycles often last 8-16 weeks, followed by a break to preserve pituitary sensitivity.

Dosage for Research (Women)

Research dosing for female subjects is generally similar but often starts at the lower end of the range (e.g., 100 mcg per dose) due to typically higher endogenous GH sensitivity. The same multi-daily administration protocol applies to leverage natural pulse patterns. Researchers should note that women may experience more pronounced effects on fat metabolism at lower doses. As always, protocol design should be conservative and observation-based.

Active Life and Half-Life

CJC-1295 No DAC has a plasma half-life of approximately 30 minutes. Its biological activity in stimulating a GH pulse, however, results in elevated GH levels for about 90-120 minutes post-injection. This short active life is intentional and desirable, as it creates a sharp, physiological pulse rather than a prolonged, steady-state elevation. This necessitates multiple daily injections in research settings to achieve the desired frequency of GH pulses.

CJC-1295 No DAC Side Effects

Research indicates a favorable side effect profile at standard doses. The most commonly reported effects in studies are related to the GH pulse itself and can include transient flushing, warmth, or mild headache shortly after injection—often a sign of GH release. Unlike the DAC version, the No DAC variant carries a much lower risk of side effects associated with constant GH elevation, such as water retention, joint pain, or carpal tunnel syndrome. Injection site reactions are possible but rare with proper technique.

Contraindications and Precautionary Measures

CJC-1295 No DAC is contraindicated in research involving subjects with active or suspected neoplasms (cancers), as GH and IGF-1 can promote cell growth. Caution is advised in research designs involving subjects with diabetes or insulin resistance, as GH has anti-insulin effects. It should not be used by subjects with known hypersensitivity to the peptide. It is for research use only in laboratory settings.

Overdosage in Research

Exceeding research-level doses significantly could amplify the side effect profile, potentially leading to more pronounced flushing, headache, nausea, or symptoms of acromegaly (like tingling in hands/feet) if sustained over long periods. The peptide's short half-life limits the duration of any single overdosage event. Management in research involves cessation and supportive measures. Adherence to microgram dosing is critical.

CJC-1295 No DAC Stack/Cycle for Research

CJC-1295 No DAC is almost exclusively researched in combination with a Growth Hormone Releasing Peptide (GHRP) for powerful synergy. This creates a complete "GH secretagogue stack." Potential research combinations include:

• Ipamorelin - The most common and selective stack, researched for strong GH pulses with minimal hunger or prolactin effects.
• GHRP-2 - For research into more potent GH release and increased hunger, which can be useful for mass-gaining phases.
• Hexarelin - For studying very powerful GH pulses, though with more potential for desensitization and prolactin/cortisol increase.
• Tesamorelin - As an alternative GHRH analog for comparative studies on GH release profiles and visceral fat reduction.
• MOTS-c - To investigate the intersection of mitochondrial peptide signaling (MOTS-c) with the traditional GH/IGF-1 axis for metabolic research.

These stacks are considered the cornerstone of modern GH-secretagogue research.

Package Presentation

The product is supplied as one sterile glass vial containing 5 mg of CJC-1295 No DAC as a white lyophilized powder. The vial is sealed with a rubber stopper and aluminum crimp cap to ensure sterility until reconstitution. Packaging is discreet and secure.

Storage

For long-term stability, store the lyophilized powder at or below -20°C (-4°F). For short-term use (a few weeks), refrigeration at 2-8°C (36-46°F) is acceptable. After reconstitution with bacteriostatic water, the solution must be refrigerated and used within the timeframe recommended for peptides (typically 7-14 days) to maintain potency, as its short native sequence can degrade.

CJC-1295 No DAC Referrers

The development and pharmacology of CJC-1295 and its analogs are documented in endocrine and peptide literature. Key references include clinical studies on GHRH analogs and their effects on GH secretion profiles. Researchers should consult primary sources on the somatotropic axis, peptide half-life extension strategies, and comparative studies between GHRH analogs with and without DAC to fully understand the research context of this compound.

Third-Party Lab Test

2025-09-29

View Result

4.78 mg